09 december 2022 

Publication in Nature Medicine

We are delighted to share that the first results from the ALICE-trial were yesterday published in Nature Medicine and presented at San Antonio Breast Cancer Symposium. Thanks to the patients and the study teams at Oslo University Hospital, Stavanger University Hospital, St Olav, Rigshospitalet Copenhagen and Vejle Hospital.

From the left.., Bjørn Naume, Andras H. Røssevold, Jon Amund Kyte, Randi Mathisen, Bjørnar Gilje


ALICE is a study that for the past five years has tried to find a better treatment for patients with metastatic triple-negative breast cancer. This group has poor prognosis with a median survival of approx. one year.

70 patients from three university hospitals in Norway (Ous, Stavanger and St. Olav) and two hospitals from Denmark (Rigshospitalet and Velje) have been included in the study.

The study is a randomized, placebo-controlled study: The patients were divided into two groups, one of which received a combination of chemotherapy and immunotherapy (Atezolizumab), while the patients in the other group received chemotherapy and placebo medicine.

Previous studies have shown that immunotherapy is only effective against immune-activated disease (PD-L1-positive), but the ALICE study shows that combination treatment with chemotherapy and immunotherapy can also have an effect on patients who have not triggered the immune response in the first place (PD-L1-negative).

If the study is correct, it could change treatment worldwide for metastatic triple-negative breast cancer. It may also be important for other types of cancer, as it seems that selected types of chemotherapy can turn non-responders into responders.

Source: OUS and Jon Amund Kyte

Read more about the publication on, Kreftforeningen og Matrix

Read the interview with Jon Amund Kyte and Andreas H. Røssvold at Healthtalk or listen at NRK radio (interview begins at 30:57)

06 december 2022

Twitter: @cancertrial_ous

The Clinical Cancer Research Unit (CRU) is now on Twitter!

Follow us on @cancertrial_ous

01 september 2022

New Head of Study Nurse Unit

Melanie Schulz-Jaavall takes over as new Head of Unit for study nurses after Nina Langberg retires. 

22 juni 2022

Public defence: Elin Aamdal

Oncologist Elin Aamdal defended her thersis:"Treating metastatic  melanoma with ipilimumab – Clinical activity, health-related quality of life and combination with a telomerase peptide vaccine". 

 04 april 2022

MITRIC - New study open for inclusion 

The MITRIC study is now open for inclusion of patients with melanoma, kidney cancer, head-neck cancer, squamous cell carcinoma of the skin or microsatellite unstable (MSI positive) type of cancer. The study is relevant for patients who have been through standard treatment with immunotherapy, but the treatment has not had an effect.

Read more about the study at Oslo University Hospital 

11 october 21

PRO-GLIO - Håper ny studie kan gi svar om protonterapi

There is little research on the effect of proton therapy compared to regular radiation therapy. Soon, Norwegian brain cancer patients can participate in a study that can hopefully provide some more answers.

Interview in norwegian with researcher and oncologist Petter Brandal about the planned PRO-GLIO study.

21 september 21

Instagram: kreftforskning_ous

Department of Clinical Cancer Research is now on Instagram! Here we plan to publish news and show our work day.

Follow us @ kreftforskning_ous

21 september 20

Interview with Head of Department of Experimental Cancer Jon Amund Kyte by Pharma Boardroom 

Oncologist Jon Amund Kyte shares some of the groundbreaking immunotherapy research that he and his team is conducting at Oslo University Hospital. Kyte also explores how Norway can better develop its clinical footprint and what his hopes for the future of experimental cancer treatment in the country are.

15 september 20

BM7PE - New study for colorectal cancer open for inclusion 

A phase I/II study with BM7PE immunotoxin in colorectal cancer patients with metastactic  disease who are refractory to or with intolerance to last line of standard chemotherapy.

Read more about the study at Oslo University Hospital